Skip to main content

Rituximab in patients with acute myocardial infarction: a phase 2 placebo-controlled randomised clinical trial

Project description

Repurposing a leukaemia drug against heart failure

Acute myocardial infarction (MI) causes left ventricular dysfunction and heart failure in nearly 50 % of patients. Following extensive preclinical testing, the EU-funded RITA-MI 2 project aims to repurpose an existing drug, rituximab, currently employed for lymphoid malignancies and autoimmune disorders such as rheumatoid arthritis. Rituximab is a monoclonal antibody that selectively targets mature B lymphocytes expressing CD20. The rationale is to stop or limit the deleterious cardiac remodelling that takes place after MI and improve heart function recovery. RITA-MI 2 will assess the impact of B lymphocyte depletion in patients with MI in a phase 2b clinical trial.

Call for proposal

H2020-SC1-2020-Two-Stage-RTD
See other projects for this call

Coordinator

INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE
Address
Rue De Tolbiac 101
75654 Paris
France
Activity type
Research Organisations
EU contribution
€ 258 750

Participants (12)

ASSISTANCE PUBLIQUE HOPITAUX DE PARIS
France
EU contribution
€ 2 569 325,75
Address
3 Avenue Victoria
75000 Paris
Activity type
Research Organisations
PAPWORTH HOSPITAL NHS FOUNDATION TRUST
United Kingdom
EU contribution
€ 315 336,25
Address
Papworth Everard
CB23 3RE Cambridge
Activity type
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
KLINIKUM RECHTS DER ISAR DER TECHNISCHEN UNIVERSITAT MUNCHEN
Germany
EU contribution
€ 311 187,50
Address
Ismaninger Strasse 22
81675 Muenchen
Activity type
Higher or Secondary Education Establishments
INSTITUTO INVESTIGACION SANITARIA FUNDACION JIMENEZ DIAZ
Spain
EU contribution
€ 383 500
Address
Avenida De Los Reyes Catolicos 2
28040 Madrid
Activity type
Research Organisations
REGION UPPSALA
Sweden
EU contribution
€ 314 000
Address
Po Box 602
751 25 Uppsala
Activity type
Public bodies (excluding Research Organisations and Secondary or Higher Education Establishments)
CLALIT HEALTH SERVICES
Israel
EU contribution
€ 288 250
Address
Arlozorov Street 101
62098 Tel Aviv
Activity type
Research Organisations
IMPERIAL COLLEGE OF SCIENCE TECHNOLOGY AND MEDICINE
United Kingdom
EU contribution
€ 114 625
Address
South Kensington Campus Exhibition Road
SW7 2AZ London
Activity type
Higher or Secondary Education Establishments
FAKULTNI NEMOCNICE KRALOVSKE VINOHRADY
Czechia
EU contribution
€ 629 437,50
Address
Srobarova 50
100 34 Praha
Activity type
Research Organisations
UNIVERSITEIT MAASTRICHT
Netherlands
EU contribution
€ 615 123,75
Address
Minderbroedersberg 4
6200 MD Maastricht
Activity type
Higher or Secondary Education Establishments
CHARITE - UNIVERSITAETSMEDIZIN BERLIN
Germany
EU contribution
€ 181 895
Address
Chariteplatz 1
10117 Berlin
Activity type
Higher or Secondary Education Establishments
THE CHANCELLOR MASTERS AND SCHOLARS OF THE UNIVERSITY OF CAMBRIDGE
United Kingdom
EU contribution
€ 235 910
Address
Trinity Lane The Old Schools
CB2 1TN Cambridge
Activity type
Higher or Secondary Education Establishments
INSERM TRANSFERT SA
France
EU contribution
€ 365 875
Address
Rue Watt 7
75013 Paris
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)